Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by DigitalSpurson Apr 30, 2020 1:01pm

91 Views

Post# 30972111

RE:RE:RE:Another big gap to fill soon !!

Not concerned here.

The entire market was down (I follow 10 stocks across different sectors) and all started in the green today - some as high as 15%, but are all now at a 2-5% loss for the day.

I think we will see it definitely jump over 50 cents before close and potentially close near the day high.

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal